Sir, the effect of TUBULOGLOMERULAR FEEDBACK is mediated via effects on afferent arteriola or efferent arteriole..?? That is in case of DM, there is decrease in distal delivery of Na+ to macula densa (d/t SGLT2 activation and tubular hypertrophy) which results in afferent arteriole dilation and increase in GFR According to your presentation , TGF is linked to RAAS....? Loss of TGF results in efferent arteriole constriction or afferent arteriole dilation..??
Even i got confused...isn't the TGF working well in diabetes n that's y it is adding fuel to fire by further by causing efferent vasoconstriction at first place....with SGLT2i we are inhibiting TGF of renin release right
Side effects are inevitable however do we have inputs on the long-term use of SGLT 2 drugs ?
So is UDAPA XR tablet sglt2 inhibitor for diabetic type 2 good for heart and kidneys ??
Yes
Sir, the effect of TUBULOGLOMERULAR FEEDBACK is mediated via effects on afferent arteriola or efferent arteriole..??
That is in case of DM, there is decrease in distal delivery of Na+ to macula densa (d/t SGLT2 activation and tubular hypertrophy) which results in afferent arteriole dilation and increase in GFR
According to your presentation , TGF is linked to RAAS....?
Loss of TGF results in efferent arteriole constriction or afferent arteriole dilation..??
Even i got confused...isn't the TGF working well in diabetes n that's y it is adding fuel to fire by further by causing efferent vasoconstriction at first place....with SGLT2i we are inhibiting TGF of renin release right